Table 4.

Subgroup analyses for cardiac events: the impact of PVC burden high vs low

Factor	Subgroup	N	HR (95% CI)	P value	Interaction P value
Total	—	435	2.028 (1.418‐2.901)	<.001	—
Age	≥65 y	253	1.681 (1.091‐2.590)	.019	0.231
	<65 y	182	2.634 (1.388‐4.999)	.003
Sex	Male	271	2.086 (1.300‐3.348)	.002	0.938
	Female	164	2.163 (1.225‐3.821)	.008
Ischemic etiology	Yes	75	1.156 (0.503‐2.656)	.732	0.185
	No	360	2.265 (1.521‐3.372)	<.001
NYHA functional class at discharge	I or II	426	2.044 (1.413‐2.955)	<.001	0.771
	III or IV	9	1.237 (0.272‐5.629)	.783
LVEF	≥50%	233	1.575 (0.841‐2.951)	.156	0.637
	<50%	202	1.924 (1.219‐3.039)	.005
AF	Yes	127	1.444 (0.781‐2.672)	.241	0.254
	No	308	2.223 (1.427‐3.465)	<.001
NSVT	Yes	139	1.982 (0.939‐4.183)	.073	0.471
	No	296	1.454 (0.886‐2.387)	.139
Multifocal PVCs	Yes	375	2.009 (1.368‐2.949)	<.001	0.833
	No	60	0.042 (0.000‐292.3)	.482
Hypertension	Yes	335	1.648 (1.125‐2.415)	.010	0.015
	No	100	8.366 (2.417‐28.954)	<.001
Diabetes	Yes	154	1.556 (0.925‐2.617)	.095	0.264
	No	281	2.374 (1.448‐3.890)	.001
Dyslipidemia	Yes	334	1.776 (1.191‐2.647)	.005	0.153
	No	101	3.428 (1.448‐8.113)	.005
Chronic kidney disease	Yes	230	1.544 (1.006‐2.369)	.047	0.163
	No	205	2.642 (1.370‐5.095)	.004
Anemia	Yes	217	1.462 (0.946‐2.258)	.087	0.049
	No	218	3.209 (1.689‐6.099)	<.001
Pace maker	Yes	10	29.958 (0.000‐3335438.6)	.481	0.943
	No	425	1.997 (1.390‐2.868)	<.001
ICD/CRT‐P/CRT‐D	Yes	23	2.119 (0.632‐7.105)	.224	0.842
	No	412	1.944 (1.332‐2.836)	.001
Usage of β blockers at discharge	Yes	372	1.868 (1.283‐2.720)	.001	0.295
	No	63	2.993 (0.897‐9.979)	.074
Usage of ACE inhibitors/ARBs at discharge	Yes	353	2.398 (1.624‐3.541)	<.001	0.028
	No	82	0.711 (0.258‐1.961)	.510
Usage of amiodarone at discharge	Yes	88	1.280 (0.690‐2.375)	.433	0.245
	No	347	1.990 (1.276‐3.104)	.002
Usage of digitalis at discharge	Yes	72	2.667 (1.064‐6.685)	.036	0.533
	No	363	1.872 (1.261‐2.780)	.002

Abbreviations: CI, confidence interval; HR, hazard ratio. The other abbreviations are as in Table 1 and Table 3.